Käypä hoito -työryhmä Kohdunkaulan, emättimen ja ulkosynnytinten solumuutokset
16.8.2016
Käytössä on kolme infektioita ehkäisevää HPV-rokottetta
HPV 16 ja 18 aiheuttavat noin 70 % kohdunkaulasyövistä «Clifford GM, Smith JS, Plummer M ym. Human papillo...»1.Esiasteissa näiden HPV-tyyppien syyosuus pienenee muutoksen lieventyessä.
Jotta korkean riskin HPV-tyyppien (rokotteen sisältämät virustyypit) mahdollisesti
aiheuttaman syövän kehittyminen voidaan parhaiten estää, tulee HPV-infektion estävä
rokotus antaa nuorille ennen HPV:lle altistumista eli ennen sukupuolielämän aloittamista.
Clifford GM, Smith JS, Plummer M ym. Human papillomavirus types in invasive cervical
cancer worldwide: a meta-analysis. Br J Cancer 2003;88:63-73 «PMID: 12556961»PubMed
GlaxoSmithKline Vaccine HPV-007 Study Group, Romanowski B, de Borba PC ym. Sustained
efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted
vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet
2009;374:1975-85 «PMID: 19962185»PubMed
Block SL, Brown DR, Chatterjee A ym. Clinical trial and post-licensure safety profile
of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle
vaccine. Pediatr Infect Dis J 2010;29:95-101 «PMID: 19952863»PubMed
Garland SM, Ault KA, Gall SA ym. Pregnancy and infant outcomes in the clinical trials
of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized
controlled trials. Obstet Gynecol 2009;114:1179-88 «PMID: 19935017»PubMed
Wacholder S, Chen BE, Wilcox A ym. Risk of miscarriage with bivalent vaccine against
human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled
trials. BMJ 2010;340:c712 «PMID: 20197322»PubMed
Garland SM, Ault KA, Gall SA ym. Pregnancy and infant outcomes in the clinical trials
of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized
controlled trials. Obstet Gynecol 2009;114:1179-88 «PMID: 19935017»PubMed
Paavonen J, Naud P, Salmerón J ym. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted
vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA):
final analysis of a double-blind, randomised study in young women. Lancet 2009;374:301-14
«PMID: 19586656»PubMed
Brown DR, Kjaer SK, Sigurdsson K ym. The impact of quadrivalent human papillomavirus
(HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease
due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.
J Infect Dis 2009;199:926-35 «PMID: 19236279»PubMed
Jenkins D. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted
cervical cancer vaccine: importance of virological and clinical endpoints and implications
for mass vaccination in cervical cancer prevention. Gynecol Oncol 2008;110:S18-25
«PMID: 18653221»PubMed
Ault KA. Human papillomavirus vaccines and the potential for cross-protection between
related HPV types. Gynecol Oncol 2007;107:S31-3 «PMID: 18499916»PubMed
Wheeler CM, Kjaer SK, Sigurdsson K ym. The impact of quadrivalent human papillomavirus
(HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease
due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J
Infect Dis 2009;199:936-44 «PMID: 19236277»PubMed«PMID: 19236277»PubMed
Lehtinen M, Dillner J. Clinical trials of human papillomavirus vaccines and beyond.
Nat Rev Clin Oncol 2013;10:400-10 «PMID: 23736648»PubMed
Szarewski A, Skinner SR, Garland SM ym. Efficacy of the HPV-16/18 AS04-adjuvanted
vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation.
J Infect Dis 2013;208:1391-6 «PMID: 24092907»PubMed
Muñoz N, Manalastas R Jr, Pitisuttithum P ym. Safety, immunogenicity, and efficacy
of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in
women aged 24-45 years: a randomised, double-blind trial. Lancet 2009;373:1949-57
«PMID: 19493565»PubMed
Olsson SE, Villa LL, Costa RL ym. Induction of immune memory following administration
of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like
particle (VLP) vaccine. Vaccine 2007;25:4931-9 «PMID: 17499406»PubMed
Vesikari T, Van Damme P, Lindblad N ym. An open-label, randomized, multicenter study
of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus
(types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis,
and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age. Pediatr Infect
Dis J 2010;29:314-8 «PMID: 19952980»PubMed
Joura EA, Giuliano AR, Iversen OE ym. A 9-valent HPV vaccine against infection and
intraepithelial neoplasia in women. N Engl J Med 2015;372:711-23 «PMID: 25693011»PubMed
Human papillomavirus vaccines. WHO position paper. Wkly Epidemiol Rec 2009;84:118-31
«PMID: 19360985»PubMed
Gertig DM, Brotherton JM, Budd AC ym. Impact of a population-based HPV vaccination
program on cervical abnormalities: a data linkage study. BMC Med 2013;11:227 «PMID: 24148310»PubMed
Baldur-Felskov B, Dehlendorff C, Munk C ym. Early impact of human papillomavirus vaccination
on cervical neoplasia--nationwide follow-up of young Danish women. J Natl Cancer Inst
2014;106:djt460 «PMID: 24552678»PubMed
Pollock KG, Kavanagh K, Potts A ym. Reduction of low- and high-grade cervical abnormalities
associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer 2014;111:1824-30
«PMID: 25180766»PubMed
Drolet M, Bénard É, Boily MC ym. Population-level impact and herd effects following
human papillomavirus vaccination programmes: a systematic review and meta-analysis.
Lancet Infect Dis 2015;15:565-80 «PMID: 25744474»PubMed
Anttila A, Arbyn M, De Vuyst H, Dillner J, Dillner L, Franceschi S, Patnick J, Ronco
G, Segnan N, Suonio E, Törnberg S & von Karsa L (eds.). European guidelines for quality
assurance in cervical cancer screening. Second edition, Supplements. Office for Official
Publications of the European Union, Luxembourg 2015 saatavana http://bookshop.europa.eu/en/european-guidelines-for-quality-assurance-in-cervical-cancer-screening-pbEW0115451/
WHO. Global Advisory Committee on Vaccine Safety, report of meeting held 11-12 December.
Wkly Epidemiol Rec, vol. 89, no. 7, pp. 53-60.
Castellsagué X, Muñoz N, Pitisuttithum P ym. End-of-study safety, immunogenicity,
and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult
women 24-45 years of age. Br J Cancer 2011;105:28-37 «PMID: 21629249»PubMed
Schwarz TF, Spaczynski M, Schneider A ym. Immunogenicity and tolerability of an HPV-16/18
AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine
2009;27:581-7 «PMID: 19022320»PubMed
Trimble CL, Morrow MP, Kraynyak KA ym. Safety, efficacy, and immunogenicity of VGX-3100,
a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and
E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind,
placebo-controlled phase 2b trial. Lancet 2015;386:2078-88 «PMID: 26386540»PubMed
